RESULTS OF A ONE YEAR STUDY OF THE STABILITY OF INTRAVENOUS NITROGLYCERIN IN 5% GLUTATHIONE FOR TREATING ADHF AND RIGHT HEART FAILURE POST LVAD IMPLANTATION

preprint OA: closed
Full text JSON View at publisher

Abstract

BACKGROUND : Superoxide resulting from GTN tolerance causes diuretic resistance which limits the treatment of ADHF and right heart failure post LVAD implantation. Formulating IV GTN in 5% GSH is expected to benefit both these conditions with GTN targeting heart failure and GSH preventing diuretic resistance. The purpose of this study is to evaluate the stability of a new formulation of intravenous nitroglycerin (GTN) for use in treating ADHF and right heart failure post LVAD implantation. METHODS : a new protocol for formulating IV GTN in 5% GSH that is buffered with 2% L-arginine was used to create two solutions of GTN in 5% GSH. Following this the pH of two solutions of .2 mg/cc GTN in 5% GSH prepared according to the new protocol was tested. The solutions were then stored at room temperature for one year and observed for evidence of GSH oxidation. After one year, the pH of the solutions was retested. RESULTS: initial pH ranged 4.0 +/- .05 and was unchanged after one year. Both solutions remained clear without evidence of GSH oxidation after one year. CONCLUSION : this new formulation of IV GTN in 5% GSH is stable for use in treating ADHF and right heart failure post LVAD implantation for periods of up to one year. This new formulation has the potential to reduce the need for right ventricular assist devices following LVAD implantation and facilitate the explantation of LVADs thereby reducing the need for heart transplants.
Full text 6,605 characters · extracted from preprint-html · click to expand
RESULTS OF A ONE YEAR STUDY OF THE STABILITY OF INTRAVENOUS NITROGLYCERIN IN 5% GLUTATHIONE FOR TREATING ADHF AND RIGHT HEART FAILURE POST LVAD IMPLANTATION | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 16 September 2025 V1 Latest version Share on RESULTS OF A ONE YEAR STUDY OF THE STABILITY OF INTRAVENOUS NITROGLYCERIN IN 5% GLUTATHIONE FOR TREATING ADHF AND RIGHT HEART FAILURE POST LVAD IMPLANTATION Author : Wayne Kaesemeyer 0000-0001-8498-7313 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.175798275.56717656/v1 109 views 78 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract BACKGROUND : Superoxide resulting from GTN tolerance causes diuretic resistance which limits the treatment of ADHF and right heart failure post LVAD implantation. Formulating IV GTN in 5% GSH is expected to benefit both these conditions with GTN targeting heart failure and GSH preventing diuretic resistance. The purpose of this study is to evaluate the stability of a new formulation of intravenous nitroglycerin (GTN) for use in treating ADHF and right heart failure post LVAD implantation. METHODS : a new protocol for formulating IV GTN in 5% GSH that is buffered with 2% L-arginine was used to create two solutions of GTN in 5% GSH. Following this the pH of two solutions of .2 mg/cc GTN in 5% GSH prepared according to the new protocol was tested. The solutions were then stored at room temperature for one year and observed for evidence of GSH oxidation. After one year, the pH of the solutions was retested. RESULTS: initial pH ranged 4.0 +/- .05 and was unchanged after one year. Both solutions remained clear without evidence of GSH oxidation after one year. CONCLUSION : this new formulation of IV GTN in 5% GSH is stable for use in treating ADHF and right heart failure post LVAD implantation for periods of up to one year. This new formulation has the potential to reduce the need for right ventricular assist devices following LVAD implantation and facilitate the explantation of LVADs thereby reducing the need for heart transplants. Supplementary Material File (mitogtn -v 15 - 7-16-25 mod 1.docx) Download 367.16 KB File (mitogtn v 14 -table 1 -6-11-25.docx) Download 246.92 KB Information & Authors Information Version history V1 Version 1 16 September 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Authors Affiliations Wayne Kaesemeyer 0000-0001-8498-7313 [email protected] Augusta Hypertension PC View all articles by this author Metrics & Citations Metrics Article Usage 109 views 78 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Wayne Kaesemeyer. RESULTS OF A ONE YEAR STUDY OF THE STABILITY OF INTRAVENOUS NITROGLYCERIN IN 5% GLUTATHIONE FOR TREATING ADHF AND RIGHT HEART FAILURE POST LVAD IMPLANTATION. Authorea . 16 September 2025. DOI: https://doi.org/10.22541/au.175798275.56717656/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175798275.56717656/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ffc2b258b7f0700',t:'MTc3OTQ1NjU1Mw=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00